Loading, Please Wait...
WALTHAM, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve Stimulator with automatic detection of user sleep-wake state.” The patent covers technology that automatically adapts electrical stimulation to the user’s sleep pattern. NeuroMetrix now has 11 issued U.S. utility patents covering the Quell® Wearable Pain Relief Technology™.
"We are pleased to have received this latest patent, which describes a unique on-demand overnight therapy option for chronic pain sufferers using Quell,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “We are continually improving Quell therapy options available to our users overnight because many report that pain interferes with their sleep. Quell is the only wearable transcutaneous electrical nerve stimulator that is cleared by the FDA for overnight use.”
Quell is an advanced, wearable pain-relief technology. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for relief and management of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud™, which provides customized feedback and powers one of the largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's markets Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Source: NeuroMetrix, Inc.